Benign Bone Tumors(Enchondroma
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Diagnosed with benign bone tumors (enchondroma, chondroblastoma, osteoid osteoma, osteoma, aneurysmal bone cyst, non-ossifying fibroma, fibrous dysplasia of bone) or intermediate (locally aggressive/borderline) bone tumors (atypical cartilaginous tumor, osteoblastoma, giant cell tumor of bone) according to the WHO Classification of Bone Tumors (2020 Edition); 2.Patients treated at The Third Affiliated Hospital of Southern Medical University between January 2016 and January 2024; 3.First-time recipients of curettage surgery for the lesion; 4.Tumors located exclusively in the extremities;
Exclusion criteria
Exclusion criteria: 1.History of non-musculoskeletal malignancy within the past 5 years; 2.Concurrent metastatic bone tumors or malignant transformation; 3.Prior chemotherapy, radiotherapy, or targeted therapy before surgery; 4.Critical data missing (e.g., incomplete surgical records, loss to follow-up); 5.Inability to comply with study requirements, including completion of follow-up visits or adherence to protocol-specified procedures (e.g., clinical outcome assessments), as judged by the investigator or subject; 6.Unstable systemic diseases, including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction; 7.Other conditions deemed ineligible for participation by the investigator (e.g., atypical clinical presentation or high surgical risk);
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Local recurrence and/or metastasis;Recurrence-free survival;Recurrence rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of Various Postoperative Complications;Occurrence Time; | — |
Countries
China
Contacts
The Third Affiliated Hospital of Southern Medical University